Risky Business is a weekly information security podcast featuring news and in-depth interviews with industry luminaries. Launched in February 2007, Risky Business is a must-listen digest for information security pros. With a running time of approximately 50-60 minutes, Risky Business is pacy; a security podcast without the waffle.
…
continue reading
Innehåll tillhandahållet av Pharma and BioTech News and BioTech News. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Pharma and BioTech News and BioTech News eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Pharma and Biotech Daily: Eli Lilly Stock Drops, Biogen Exceeds Expectations, and More Updates
MP3•Episod hem
Manage episode 447768435 series 3478766
Innehåll tillhandahållet av Pharma and BioTech News and BioTech News. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Pharma and BioTech News and BioTech News eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly experienced lower-than-expected sales for its weight loss and diabetes drugs in the third quarter, causing its stock to drop by over 13%. Biogen, on the other hand, exceeded expectations for its Alzheimer's drug Leqembi. Biomarin surpassed sales estimates for its drug Voxzogo, while Sage reported revenue growth for Zurzuvae. Biogen also signed a deal with Neomorph. Additionally, Lilly has modified the dosing of its Alzheimer's drug Kisunlan to lower brain swelling, and Novartis has secured expansion for its CML drug Scemblix. Small funds are investing in early-stage science, and there have been recent job openings in the biotech industry.
…
continue reading
62 episoder
MP3•Episod hem
Manage episode 447768435 series 3478766
Innehåll tillhandahållet av Pharma and BioTech News and BioTech News. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Pharma and BioTech News and BioTech News eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly experienced lower-than-expected sales for its weight loss and diabetes drugs in the third quarter, causing its stock to drop by over 13%. Biogen, on the other hand, exceeded expectations for its Alzheimer's drug Leqembi. Biomarin surpassed sales estimates for its drug Voxzogo, while Sage reported revenue growth for Zurzuvae. Biogen also signed a deal with Neomorph. Additionally, Lilly has modified the dosing of its Alzheimer's drug Kisunlan to lower brain swelling, and Novartis has secured expansion for its CML drug Scemblix. Small funds are investing in early-stage science, and there have been recent job openings in the biotech industry.
…
continue reading
62 episoder
All episodes
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.